News

Gilead Sciences posted a net income of $852m for the first quarter 2010, compared to $586.57m for the prior year period. Income from operations was $1.16bn, compared to

Amylin Pharmaceuticals has posted total revenues of $174.13m, which includes net product sales of $172.3m, for the first quarter 2010, compared to $180.4m for the year ago period.

The AllegroGraph-Sentient framework allows users to integrate, analyse and use complex data at a fraction of the cost and time typically required. This reduces the cost and lag-time

Dr Kontny joins Patheon from Abbott Laboratories, where he was divisional vice president of global pharmaceutical and analytical sciences for its global pharmaceutical research and development organisation. Wes

Sandoz said that the regulatory approvals of these medicines, if achieved, would enable it to increase access to affordable, high-quality therapeutic alternatives for these increasingly prevalent diseases. The

With the addition of these two models, the Quadro FlexSift line can now handle up to 50,000kgs/hr (110,000 lbs/hr) dependent upon the product being screened. Both new models

Diquafosol was licensed for certain ophthalmic uses from Inspire and Diquas Ophthalmic Solution 3% was developed by Santen as a treatment for dry eye. Reportedly, in clinical studies

Enigma said that this is the recent patent to issue in company’s expanding portfolio of over 300 patents and patent applications. The portfolio includes patents relating to intelligent

Rezaltas is a combination drug featuring the Daiichi Sankyo-developed olmesartan medoxomil (Olmetec), a high-affinity ARB (angiotensin receptor blocker) and azelnidipine (Calblock), a long-acting CCB (calcium channel blocker) that